ZYME
Zymeworks Inc.
$23.93
-0.46%
$1.7B
No data for this timeframe.
Vol
Market Cap$1.7B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (95%)
Inst. Holders7 funds
Inst. Value$163.8M
Inst. Activity1 buys / 3 sells
SEC Reports3
Press Releases5
Recent Activity
Aug 25, 2026
fda_pdufa
PDUFA: ZYME — Ziihera in first-line HER2-positive unresectable locally advanced or metastatic gastroesophageal adenocarcinoma (GEA) — 2026-08-25
FDA target action date 2026-08-25 for ZYME (Zymeworks Inc.). Drug: Ziihera. Indication: first-line H
May 15, 2026
SEC
Form 3 filing for Paul R. Schneider, EVP and General Counsel of Zymeworks Inc., reports zero beneficial ownership. This
3 — Impact 2/10
May 13, 2026
Insider
Schneider Paul R sold 178,000 shares
EVP, General Counsel @ $0.00 ($0.00)
May 13, 2026
Insider
Schneider Paul R sold 119,000 shares
EVP, General Counsel @ $0.00 ($0.00)
Apr 21, 2026
Press
Zymeworks announced positive Phase 1 data for ZW191, an FRα-targeting antibody-drug conjugate, showing a 61% confirmed o
Impact 8/10
Apr 17, 2026
Press
Zymeworks announced six preclinical poster presentations at AACR 2026 showcasing its next-generation antibody-drug conju
Impact 7/10
Apr 16, 2026
SEC
Zymeworks announced it will report Q1 2026 financial results on May 7, 2026, with no actual financials disclosed in this
PRESS-RELEASE — Impact 3/10
Apr 10, 2026
SEC
Scott Platshon, EVP and Chief Business Officer of Zymeworks, filed a Form 3 disclosing initial beneficial ownership and
3 — Impact 3/10
Price Targets
$39.23
+68.7% upside
Strong Buy
Current $23.26
Low $28.00
Median $35.00
High $58.00
13 analysts
$28.00
$58.00
Analyst Ratings
6Strong Buy
13Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 3, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| May 8, 2026 | Wells Fargo | MAINTAIN | Overweight → Overweight |
| Mar 9, 2026 | Evercore ISI Group | MAINTAIN | Outperform → Outperform |
| Mar 6, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Mar 3, 2026 | Stifel | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.42 ▼ -39.6% | $-0.61 — $0.03 | -1487% YoY | 9 |
| Next Q | $1.66 ▲ +25.1% | $-0.56 — $3.08 | 738% YoY | 9 |
| Current FY | $1.26 ▼ -7.0% | $-0.50 — $4.21 | 217% YoY | 10 |
| Next FY | $0.68 ▲ +58.9% | $-1.22 — $3.03 | -46% YoY | 9 |
Latest Reports
NEUTRAL
3
2/10
Form 3 filing for Paul R. Schneider, EVP and General Counsel of Zymeworks Inc., reports zero beneficial ownership. This
May 15, 2026
BULLISH
Press
8/10
Zymeworks announced positive Phase 1 data for ZW191, an FRα-targeting antibody-drug conjugate, showing a 61% confirmed o
Apr 21, 2026
NEUTRAL
PRESS-RELEASE
3/10
Zymeworks announced it will report Q1 2026 financial results on May 7, 2026, with no actual financials disclosed in this
Apr 16, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| MORGAN STANLEY | $68.3M | TRIM |
| VANGUARD GROUP INC | $61.3M | ADD |
| FMR LLC | $14.7M | DOUBLED |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $5.8M | ADD |
| RENAISSANCE TECHNOLOGIES LLC | $5.8M | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 13, 2026 | Schneider Paul | A | $0.00 |
| May 13, 2026 | Schneider Paul | A | $0.00 |
| Apr 9, 2026 | Platshon Scott | A | $0.00 |
| Apr 9, 2026 | Schayowitz Adam | A | $0.00 |
| Apr 9, 2026 | Schayowitz Adam | A | $0.00 |
7 institutional holders with $163.8M total value (6,221,516 shares) as of 2025-Q4. Top holders: MORGAN, VANGUARD, FMR. Net selling activity: 3 institutions trimmed/exited vs 1 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | MORGAN STANLEY | 2,593,080 | $68.3M | 41.7% | TRIM -34.9% |
| 2 | VANGUARD GROUP INC | 2,328,727 | $61.3M | 37.4% | ADD +39.5% |
| 3 | FMR LLC | 560,086 | $14.7M | 9.0% | DOUBLED +15838.7% |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 220,909 | $5.8M | 3.6% | ADD +55.7% |
| 5 | RENAISSANCE TECHNOLOGIES LLC | 220,877 | $5.8M | 3.6% | TRIM -48.8% |
| 6 | WELLS FARGO & COMPANY/MN | 208,313 | $5.5M | 3.3% | ADD +65.9% |
| 7 | BANK OF AMERICA CORP /DE/ | 89,524 | $2.4M | 1.4% | TRIM -48.9% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | TRIM | 3,984,585 | 2,593,080 | -34.9% | $68.3M | 2025-Q4 |
| FMR LLC | DOUBLED | 3,514 | 560,086 | +15838.7% | $14.7M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 431,700 | 220,877 | -48.8% | $5.8M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 175,327 | 89,524 | -48.9% | $2.4M | 2025-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 124,204 | 193,360 | +55.7% | $3.3M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | ADD | 90,378 | 175,327 | +94.0% | $3.0M | 2025-Q3 |
| UBS Group AG | NEAR_EXIT | 251,510 | 51,841 | -79.4% | $885.4K | 2025-Q3 |
| NORGES BANK | EXIT | 201,700 | 0 | -100.0% | $0.00 | 2025-Q3 |
| VANGUARD GROUP INC | ADD | 1,767,041 | 2,464,693 | +39.5% | $30.9M | 2025-Q2 |
| NORGES BANK | NEW | — | 201,700 | — | $2.5M | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | ADD | 100,309 | 166,428 | +65.9% | $2.1M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | ADD | 62,131 | 90,378 | +45.5% | $1.1M | 2025-Q2 |
| FMR LLC | NEAR_EXIT | 12,830 | 3,110 | -75.8% | $39.0K | 2025-Q2 |
| VANGUARD GROUP INC | TRIM | 2,493,288 | 1,767,041 | -29.1% | $21.0M | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 285,700 | 450,600 | +57.7% | $5.4M | 2025-Q1 |
| CITADEL ADVISORS LLC | DOUBLED | 75,258 | 245,370 | +226.0% | $2.9M | 2025-Q1 |
| UBS Group AG | ADD | 166,896 | 214,300 | +28.4% | $2.6M | 2025-Q1 |
| WELLS FARGO & COMPANY/MN | TRIM | 164,058 | 100,309 | -38.9% | $1.2M | 2025-Q1 |
| FMR LLC | TRIM | 21,966 | 12,830 | -41.6% | $152.8K | 2025-Q1 |
| NORGES BANK | EXIT | 201,700 | 0 | -100.0% | $0.00 | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 184,600 | 285,700 | +54.8% | $4.2M | 2024-Q4 |
| CITADEL ADVISORS LLC | ADD | 51,508 | 75,258 | +46.1% | $1.1M | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 132,798 | — | $1.7M | 2024-Q3 |
4 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 13, 2026 | Schneider Paul R | EVP, General Counsel | A | 178,000 | $0.00 | $0.00 |
| May 13, 2026 | Schneider Paul R | EVP, General Counsel | A | 119,000 | $0.00 | $0.00 |
| Apr 9, 2026 | Platshon Scott | EVP, Chief Business Officer | A | 70,000 | $0.00 | $0.00 |
| Apr 9, 2026 | Schayowitz Adam | See Remarks | A | 76,000 | $0.00 | $0.00 |
| Apr 9, 2026 | Schayowitz Adam | See Remarks | A | 70,000 | $0.00 | $0.00 |
| Apr 9, 2026 | Schayowitz Adam | See Remarks | A | 47,000 | $0.00 | $0.00 |
| Apr 9, 2026 | Platshon Scott | EVP, Chief Business Officer | A | 47,000 | $0.00 | $0.00 |
| Apr 9, 2026 | Platshon Scott | EVP, Chief Business Officer | A | 76,000 | $0.00 | $0.00 |
| Apr 6, 2026 | Stafford Kristin | EVP, Chief Financial Officer | A | 178,000 | $0.00 | $0.00 |
| Apr 6, 2026 | Stafford Kristin | EVP, Chief Financial Officer | A | 119,000 | $0.00 | $0.00 |
3 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 3 neutral. Avg impact: 2.7/10.
NEUTRAL
3
2/10
Form 3 filing for Paul R. Schneider, EVP and General Counsel of Zymeworks Inc., reports zero benefic
May 15, 2026
NEUTRAL
PRESS-RELEASE
3/10
Zymeworks announced it will report Q1 2026 financial results on May 7, 2026, with no actual financia
Apr 16, 2026
NEUTRAL
3
3/10
Scott Platshon, EVP and Chief Business Officer of Zymeworks, filed a Form 3 disclosing initial benef
Apr 10, 2026
BULLISH
8/10
Zymeworks announced positive Phase 1 data for ZW191, an FRα-targeting antibody-drug conjugate, showi
Apr 21, 2026
BULLISH
7/10
Zymeworks announced six preclinical poster presentations at AACR 2026 showcasing its next-generation
Apr 17, 2026
NEUTRAL
3/10
Zymeworks announced the acceptance of an oral presentation and six abstracts from its R&D portfolio
Mar 17, 2026
BULLISH
7/10
Zymeworks secured $250 million in non-dilutive financing from Royalty Pharma through a royalty-backe
Mar 2, 2026
BULLISH
8/10
Zymeworks reported strong 2025 financial results with 39% revenue growth to $106.0 million and a 34%
Mar 2, 2026
Current analyst consensus: Strong Buy (95% buy). Based on 20 analysts: 6 strong buy, 13 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$39.23 mean target
+68.7% upside
Strong Buy (1.14)
$28.00 Low
$58.00 High
| Metric | Value |
|---|---|
| Current Price | $23.26 |
| Target Low | $28.00 |
| Target Mean | $39.23 |
| Target Median | $35.00 |
| Target High | $58.00 |
| # Analysts | 13 |
| Recommendation | Strong Buy (1.14) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.42 | $-0.61 | $0.03 | -1487.0% | -39.6% | 0↑ 4↓ | $0.0B | -65.7% | 9 |
| Next Q 2026-09-30 |
$1.66 | $-0.56 | $3.08 | 737.7% | +25.1% | 3↑ 1↓ | $0.2B | 607.6% | 9 |
| Current FY 2026-12-31 |
$1.26 | $-0.50 | $4.21 | 217.1% | -7.0% | 3↑ 2↓ | $0.3B | 188.9% | 10 |
| Next FY 2027-12-31 |
$0.68 | $-1.22 | $3.03 | -45.9% | +58.9% | 3↑ 1↓ | $0.2B | -24.6% | 9 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.416 | |
| 7d ago | $-0.392 | -0.024 |
| 30d ago | $-0.298 | -0.118 |
| 60d ago | $-0.189 | -0.228 |
| 90d ago | $-0.189 | -0.228 |
6 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 3, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 8, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Mar 9, 2026 | Evercore ISI Group | MAINTAIN | Outperform | Outperform |
| Mar 6, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 3, 2026 | Stifel | MAINTAIN | Buy | Buy |
| Mar 3, 2026 | Leerink Partners | MAINTAIN | Outperform | Outperform |
| Dec 17, 2025 | Truist Securities | INITIATE | — | Buy |
| Dec 12, 2025 | Wells Fargo | UPGRADE | Equal-Weight | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 6 | 13 | 1 | 0 | 0 | 95% | |
| May 1, 2026 | 6 | 13 | 1 | 0 | 0 | 95% | |
| Apr 1, 2026 | 6 | 13 | 1 | 0 | 0 | 95% | |
| Mar 1, 2026 | 6 | 13 | 1 | 0 | 0 | 95% | |
| Feb 1, 2026 | 6 | 13 | 1 | 0 | 0 | 95% | |
| Jan 1, 2026 | 6 | 13 | 1 | 0 | 0 | 95% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Aug 25, 2026
fda_pdufa
PDUFA: ZYME — Ziihera in first-line HER2-positive unresectable locally advanced or metastatic gastroesophageal adenocarcinoma (GEA) — 2026-08-25
FDA target action date 2026-08-25 for ZYME (Zymeworks Inc.). Drug: Ziihera. Indication: first-line HER2-positive unresectable locally advanced or meta
May 13, 2026
other
Zymeworks Announces Participation in Upcoming Investor Conferences
<p>VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of lice
May 7, 2026
earnings_calendar
ZYME Q1 2026 Earnings Scheduled — 2026-05-07
Apr 21, 2026
fda
Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026
<p>VANCOUVER, British Columbia, April 21, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of li
Apr 17, 2026
fda
Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform
<p>VANCOUVER, British Columbia, April 17, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of l
Apr 16, 2026
earnings
Zymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026
<p align="left">VANCOUVER, British Columbia, April 16, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a po
Apr 9, 2026
other
Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth
<p align="center"><em>• Adam Schayowitz, Ph.D., MBA appointed as Head of R&D<br></em><em>• Scott Platshon appointed as Chief Business Officer </em
Apr 1, 2026
other
Zymeworks Appoints Kristin Stafford as Chief Financial Officer
<p>VANCOUVER, British Columbia, April 01, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of li
Mar 30, 2026
other
Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate
<p>VANCOUVER, British Columbia, March 30, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of li
Mar 24, 2026
other
Zymeworks Announces Participation in Upcoming Investor Conferences
<p>VANCOUVER, British Columbia, March 24, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of li
Mar 18, 2026
routine
Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting
Four presentations deliver new insights into zanidatamab, including its differentiated HER2 biology <pre>Four presentations deliver new insights into
Mar 17, 2026
fda
Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting
<p>VANCOUVER, British Columbia , March 17, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of l
Mar 2, 2026
contract
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing
<p align="left">VANCOUVER, British Columbia and NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Yp8
Mar 2, 2026
earnings
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
<p>VANCOUVER, British Columbia, March 02, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of li
Mar 2, 2026
earnings_calendar
ZYME Q4 2025 Earnings After Market Close — 2026-03-02